SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel.
COVID-19
SARS-CoV-2
breakthrough infections
immune response
mRNA vaccine against SARS-CoV-2
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
23 Apr 2023
23 Apr 2023
Historique:
received:
02
03
2023
revised:
19
04
2023
accepted:
22
04
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
Vaccine-induced SARS-CoV-2-anti-spike antibody (anti-S/RBD) titers are often used as a marker of immune protection and to anticipate the risk of breakthrough infections, although no clear cut-off is available. We describe the incidence of SARS-CoV-2 vaccine breakthrough infections in COVID-19-free personnel of our hospital, according to B- and T-cell immune response elicited one month after mRNA third dose vaccination. The study included 487 individuals for whom data on anti-S/RBD were available. Neutralizing antibody titers (nAbsT) against the ancestral Whuan SARS-CoV-2, and the BA.1 Omicron variant, and SARS-CoV-2 T-cell specific response were measured in subsets of 197 (40.5%), 159 (32.6%), and 127 (26.1%) individuals, respectively. On a total of 92,063 days of observation, 204 participants (42%) had SARS-CoV-2 infection. No significant differences in the probability of SARS-CoV-2 infection for different levels of anti-S/RBD, nAbsT, Omicron nAbsT, or SARS-CoV-2 T cell specific response, and no protective thresholds for infection were found. Routine testing for vaccine-induced humoral immune response to SARS-CoV-2 is not recommended if measured as parameters of 'protective immunity' from SARS-CoV-2 after vaccination. Whether these findings apply to new Omicron-specific bivalent vaccines is going to be evaluated.
Sections du résumé
BACKGROUND
BACKGROUND
Vaccine-induced SARS-CoV-2-anti-spike antibody (anti-S/RBD) titers are often used as a marker of immune protection and to anticipate the risk of breakthrough infections, although no clear cut-off is available. We describe the incidence of SARS-CoV-2 vaccine breakthrough infections in COVID-19-free personnel of our hospital, according to B- and T-cell immune response elicited one month after mRNA third dose vaccination.
METHODS
METHODS
The study included 487 individuals for whom data on anti-S/RBD were available. Neutralizing antibody titers (nAbsT) against the ancestral Whuan SARS-CoV-2, and the BA.1 Omicron variant, and SARS-CoV-2 T-cell specific response were measured in subsets of 197 (40.5%), 159 (32.6%), and 127 (26.1%) individuals, respectively.
RESULTS
RESULTS
On a total of 92,063 days of observation, 204 participants (42%) had SARS-CoV-2 infection. No significant differences in the probability of SARS-CoV-2 infection for different levels of anti-S/RBD, nAbsT, Omicron nAbsT, or SARS-CoV-2 T cell specific response, and no protective thresholds for infection were found.
CONCLUSIONS
CONCLUSIONS
Routine testing for vaccine-induced humoral immune response to SARS-CoV-2 is not recommended if measured as parameters of 'protective immunity' from SARS-CoV-2 after vaccination. Whether these findings apply to new Omicron-specific bivalent vaccines is going to be evaluated.
Identifiants
pubmed: 37238918
pii: biomedicines11051247
doi: 10.3390/biomedicines11051247
pmc: PMC10215853
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : Ricerca corrente Linea 1
Références
J Neurol Neurosurg Psychiatry. 2023 Apr;94(4):290-299
pubmed: 36522154
Liver Int. 2023 May;43(5):1120-1125
pubmed: 36929682
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Immunol Rev. 2022 Sep;310(1):27-46
pubmed: 35733376
Int J Infect Dis. 2022 Dec;125:195-208
pubmed: 36328289
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Lancet Infect Dis. 2022 Jun;22(6):802-812
pubmed: 35271805
Nat Commun. 2022 Aug 22;13(1):4922
pubmed: 35995780
Front Immunol. 2022 Jun 23;13:907343
pubmed: 35812411
Front Immunol. 2021 Sep 29;12:742914
pubmed: 34659237
Sci Transl Med. 2022 Mar 23;14(637):eabn8057
pubmed: 35166573
Biomedicines. 2021 Dec 27;10(1):
pubmed: 35052727
Nat Med. 2022 Mar;28(3):477-480
pubmed: 35046572
J Clin Med. 2022 Mar 19;11(6):
pubmed: 35330029
J Med Virol. 2022 May;94(5):1825-1832
pubmed: 35023191
N Engl J Med. 2022 Sep 15;387(11):1011-1020
pubmed: 36044620
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Pathogens. 2022 Aug 05;11(8):
pubmed: 36015003
Microorganisms. 2021 Jun 16;9(6):
pubmed: 34208751
Vaccines (Basel). 2021 Jun 08;9(6):
pubmed: 34201065
Emerg Microbes Infect. 2022 Dec;11(1):1262-1271
pubmed: 35412409
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
Ann Intern Med. 2022 Dec;175(12):1693-1706
pubmed: 36215715
PLoS One. 2022 Apr 8;17(4):e0266852
pubmed: 35395052
Microbiol Spectr. 2022 Oct 26;10(5):e0202622
pubmed: 36121258
J Intern Med. 2023 Jun;293(6):694-703
pubmed: 36682036
Vaccines (Basel). 2021 Nov 19;9(11):
pubmed: 34835288
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
J Infect Dis. 2022 Nov 1;226(9):1593-1607
pubmed: 35429399
Clin Infect Dis. 2022 Sep 05;:
pubmed: 36063397
JAMA Netw Open. 2022 Sep 1;5(9):e2232760
pubmed: 36136332
Clin Chem Lab Med. 2021 Sep 08;59(12):2010-2018
pubmed: 34492749
Viruses. 2021 Apr 10;13(4):
pubmed: 33920222
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281